Kolinpharma posts 76% revenue growth in nutraceuticals

Kolinpharma, an innovative SME operating in the nutraceutical sector and listed on the AIM Italia segment of the Italian stock market, posted an exceptional performance in 2018.

Revenue surged to €7.2 million (up 76% from the €4.1 million of 2017), while EBITDA more than doubled (up 139% to €1.45 million). Net profit also increased to €300,000.

In the 2019 financial year, the company intends to continue to develop products for high-growth therapeutic categories and to identify innovative formulations for new areas of specialisation where there is a strong need for supplements to support pharmacological therapies.

As part of its internationalisation plan, Kolinpharma is looking at a series of European and non-European countries with a favourable regulatory environment and high market potential where it could register and gradually introduce its products and then search for local partners or dealers for distribution agreements.